[Pubmed] Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab
Posté : 05 mai 2025 12:00
Autoimmun Rev. 2025 May 3:103826. doi: 10.1016/j.autrev.2025.103826. Online ahead of print.
ABSTRACT
Interleukin-6 (IL-6) is a multifunctional cytokine produced by various cells of the innate and adaptive immune systems. It acts as a regulatory factor in immunity, inflammation, metabolism, and cellular function in multiple organs and systems. The functionality of IL-6 is achieved through multiple signal transduction pathways, such as the JAK/STAT and the NF-κB signaling pathways. In this review, we highlighted the inflammatory and non-inflammatory functions of IL-6, as well as the associated signaling pathways. The involvement of IL-6 in neuroimmunological disorders suggests that the interleukin-6 receptor (IL-6R) monoclonal antibody, satralizumab, is a potential therapeutic strategy. Phase III clinical trials have already validated the safety and efficiency of satralizumab in treating neuromyelitis optica spectrum disorders (NMOSD) and acetylcholine receptor (AChR) seropositive generalized myasthenia gravis (gMG). This review aims to elucidate the pathophysiological role of IL-6, and explore the clinical implications of satralizumab in neuroimmunological diseases, providing insights into its potential therapeutic applications.
PMID:40324548 | DOI:10.1016/j.autrev.2025.103826
Source: https://pubmed.ncbi.nlm.nih.gov/4032454 ... t9+e462414